431 related articles for article (PubMed ID: 23877438)
21. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
22. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Shinmura K; Kageyama S; Tao H; Bunai T; Suzuki M; Kamo T; Takamochi K; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
Lung Cancer; 2008 Aug; 61(2):163-9. PubMed ID: 18242762
[TBL] [Abstract][Full Text] [Related]
23. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
24. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
25. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
Wijesinghe P; Bepler G; Bollig-Fischer A
J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.
Ren S; Huang S; Ye X; Feng L; Lu Y; Zhou C; Zhao J; He T; Wang J; Li B
Cancer Treat Res Commun; 2021; 27():100377. PubMed ID: 33945921
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
29. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
30. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
31. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
[TBL] [Abstract][Full Text] [Related]
32. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
34. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
35. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
36. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
37. Coexistence of three variants involving two different fusion partners of ROS1 including a novel variant of ROS1 fusions in lung adenocarcinoma: a case report.
Cai W; Li W; Ren S; Zheng L; Li X; Zhou C
J Thorac Oncol; 2014 Jun; 9(6):e43-6. PubMed ID: 24828671
[No Abstract] [Full Text] [Related]
38. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
39. 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.
Gong B; Oh-Hara T; Fujita N; Katayama R
Biochem Biophys Res Commun; 2018 Jun; 501(2):527-533. PubMed ID: 29738763
[TBL] [Abstract][Full Text] [Related]
40. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]